Aiming to transform mental health care with psilocybin.

APEX is a patient-driven pharmaceutical company 

Our mission: Develop clinically evaluate and commercialize psilocybin drugs to address the most critical unmet need in depression and PTSD.

Our vision: Explore a new standard of care in mental health where physicians can access and prescribe APEX drugs globally.

Exploring a new standard of care 

The National Institute of Health reports the current rate of effectiveness with antidepressant standard of care therapy is between 40-60%, with 50% of people treated reporting unwanted side effects.

It’s time we explore new options. 

Market Opportunity

  • 1
  • 2
  • 3

  • 322 million

    People globally deal with depression

  • 280 million

    People globally suffer from PTSD

  • $19.5 Billion USD

    Forecasted size of the anxiety disorder and depression treatment markets by 2028